August 18, 2025- Mayo Clinic cardiovascular researchers created a solution for detecting cardiac amyloidosis using artificial intelligence (AI) and echocardiography. The findings of the multicenter collaboration were published in the European Heart Journal.
The AI-enhanced echocardiography model developed by Mayo Clinic and an AI echocardiography company is the initial and only tool of its kind. “Our model was approved by the FDA as a breakthrough device. It became the first commercially available AI echocardiography device to screen for amyloid cardiomyopathy,” says Patricia A. Pellikka, M.D., a cardiologist, echocardiographer and immediate past chair of Echocardiography and Cardiovascular Imaging at Mayo Clinic in Rochester, Minnesota. Dr. Pellikka was senior author of the study.